The Enterprise Value as of November 2024 (TTM) for InflaRx N.V. (IFRX) is 92.21M

According to InflaRx N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 92.21M. This represents a change of 38.82% compared to the average of 66.42M of the last 4 quarters.

InflaRx N.V. (IFRX) Historical Enterprise Value (quarterly & annually)

How has IFRX Enterprise Value performed in the past?

The mean historical Enterprise Value of InflaRx N.V. over the last ten years is 216.85M. The current 92.21M Enterprise Value has changed 4.15% with respect to the historical average. Over the past ten years (40 quarters), IFRX's Enterprise Value was at its highest in in the March 2019 quarter at 816.62M. The Enterprise Value was at its lowest in in the June 2016 quarter at 0.

InflaRx N.V. (IFRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of InflaRx N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

InflaRx N.V. (IFRX) Average Enterprise Value

How has IFRX Enterprise Value performed in the past?

The current Enterprise Value of InflaRx N.V. (IFRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

InflaRx N.V. (IFRX) Enterprise Value vs. Peers

How is IFRX’s Enterprise Value compared to its peers?

InflaRx N.V.’s Enterprise Value is less than Generation Bio Co. (163.63M), greater than Kronos Bio, Inc. (5.32M), less than Erasca, Inc. (747.42M), less than C4 Therapeutics, Inc. (307.45M), less than Edgewise Therapeutics, Inc. (3.01B), greater than Kezar Life Sciences, Inc. (36.78M), less than Fulcrum Therapeutics, Inc. (111.82M), greater than Passage Bio, Inc. (24.72M), less than Acumen Pharmaceuticals, Inc. (139.19M), greater than Galera Therapeutics, Inc. (-7482657.00), less than Inozyme Pharma, Inc. (202.73M), less than Eledon Pharmaceuticals, Inc. (233.30M), less than Icosavax, Inc. (713.87M), greater than Ocuphire Pharma, Inc. (-9671816.00), greater than Reviva Pharmaceuticals Holdings, Inc. (33.37M), less than Protalix BioTherapeutics, Inc. (102.72M), less than EyePoint Pharmaceuticals, Inc. (552.94M), greater than SELLAS Life Sciences Group, Inc. (61.79M), less than Monte Rosa Therapeutics, Inc. (439.72M), less than Design Therapeutics, Inc. (290.40M), greater than Werewolf Therapeutics, Inc. (-1378920.00), greater than Ikena Oncology, Inc. (45.73M), less than Stoke Therapeutics, Inc. (457.69M),

Build a custom stock screener for InflaRx N.V. (IFRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like InflaRx N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

InflaRx N.V. (IFRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like InflaRx N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.